Latest Breaking News On - Prnewswire immunic inc - Page 1 : vimarsana.com

Immunic to Participate in Industry and Scientific Conferences in June

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

San diegoUnited statesDen haagZuid hollandWerner gladdinesEdna kaplanJessica breuPaula schwartzInternational conventionImmunic incRx communications groupCommunications of immunicProgram management clinical development operations of immunicExchange commissionContract management groupPrnewswire immunic inc

Immunic, Inc to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

Paula schwartzJessica breuEdna kaplanImmunic incPrnewswire immunic incExchange commissionRx communications groupPrivate securities litigation reform actMiddle eastAnnual reportPresident investor relations

Immunic, Inc Announces Private Placement of up to $240 Million

NEW YORK, Jan. 5, 2024 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.

United statesEdna kaplanPiper sandlerPaula schwartzJessica breuLadenburg thalmannPrnewswire immunic incArcadia securitiesImmunic incRx communications groupExchange commissionAvidity partnersJanus henderson investorsSoleus capitalAdage capital partnersBrookline capital markets

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Immunic Highlights 2023 Accomplishments and Upcoming Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoEdna kaplanHella kohlhofRichard rudickDaniel vittJessica breuPaula schwartzProgram in relapsing multiple sclerosis ongoingPrnewswire immunic incJp morgan health care conferenceExchange commissionRx communications groupCorporate communityImmunic incInternational business gold award

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesEdna kaplanDaniel vittJessica breuPaula schwartzPrnewswire immunic incImmunic incRx communications groupTrademark officeExchange commissionFundamental new patent covers treatmentMultiple sclerosis intoVidofludimus calciumMultiple sclerosisUnless extended furtherProtecting specific dose strength